Codiak BioSciencesÂ Inc (CDAK) Financials

$0.01

$0.00 (-25.62%)

As on 07-Jun-2023 09:30EDT

Market cap

$3 Mln

Revenue (TTM)

$34 Mln

P/E Ratio

--

P/B Ratio

0.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	33.57	22.94	2.92	0.39	--	--
Cost of Revenue	4.51	--	--	--	--	--
Gross Profit	33.57	22.94	2.92	0.39	--	--
Operating Expenses	104.73	92.48	93.83	80.54	46.44	--
Operating Profit (EBIT)	-53.30	-69.55	-90.92	-80.15	-46.44	--
Other Income	33.91	35.09	1.16	--	--	--
Profit before Tax	-39.23	-37.16	-91.67	-77.96	-44.54	--
Provision for Tax	-9.99	-33.29	-5.55	-2.19	--	--
Profit after Tax (Net Income)	-29.24	-3.87	-86.12	-75.77	-44.54	--
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-17.42	-37.16	-102.50	-91.66	-58.22	-32.74

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	38.93	53.51	14.57	21.95	92.03	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	81.01	91.00	119.12	74.26	0.73	--
Current Liabilities	14.46	27.17	17.65	19.76	4.90	3.89
Total Liabilities	148.85	171.67	151.34	115.96	97.66	--

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	73.16	81.50	57.58	21.84	6.61	--
Current Assets	61.23	90.17	93.76	94.12	91.05	127.99
Total Assets	148.85	171.67	151.34	115.96	97.66	--
Total Debt*	61.28	62.98	62.98	9.57	--	--
Net Current Assets	46.78	63.01	76.11	74.36	86.16	--

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-74.14	-63.36	-1.70	-30.57	-23.88
Cash Flow from Investing Activities	--	-3.25	52.01	-11.67	-78.54	-2.95
Cash from Financing Activities	--	65.41	89.58	9.76	-0.06	76.36
Net Cash Inflow / Outflow	--	-11.98	78.23	--	--	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	--	--	--	--	--	--
Cash EPS ($)	--	--	--	--	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	--	--	--	--
Free Cash Flow per Share ($)	--	--	--	--	--	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-3.99	-157.91	-122.65	-96.80	--
ROE (%)	-66.97	-11.37	-471.65	-132.95	-48.40	--
ROA (%)	-17.68	-2.40	-64.44	-70.94	-45.61	--
EBIT Margin (%)	-158.77	-303.24	-3,118.97	-20,657.73	--	--
Net Margin (%)	-43.32	-6.67	-2,113.87	-19,527.84	--	--
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	98.92	6.87	6.51	--	--	--
EBIT Growth (%)	22.72	23.50	-13.43	-79.95	-61.98	--
Net Profit Growth (%)	59.27	95.51	-13.66	-70.10	--	--
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	--	--	--	--	--
Price / Book Value	0.55	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-3.28	0.23	0.29	--	--	--
Close Price ($)	0.78	11.14	32.30	--	--	--
High Price ($)	17.15	37.85	32.36	--	--	--
Low Price ($)	0.75	9.67	7.90	--	--	--
Market Cap ($ Cr)	2.83	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	0.66	1.18	4.32	0.44	--	--
Short term debt to equity ratio	0.08	0.05	0.10	--	--	--
Current Ratio	4.24	3.32	5.31	4.76	18.60	32.88
Quick Ratio	4.24	3.37	--	4.65	--	--
Interest Coverage	-5.44	-25.80	-47.70	-267.17	--	--

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	--	5.62	1.06	1,523.20	--	--
Asset Turnover	0.20	0.14	0.02	0.00	--	--
Receivable days	--	10.51	372.20	5,563.47	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.